Patients with hematologic malignancies who developed chemotherapy-
Conditions
Interventions
Piperacillin/tazobactam is given in normal dose and adjusted by renal function.
Other supportive cares are given according to on primary physicians.,Meropenem is given in normal dose and adjusted by
Experimental Drug,Active Comparator Drug
Piperacillin/tazobactam,Meropenem
Sponsors
Faculty of Medicine Siriraj Hospital
Faculty of Medicine Siriraj Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adult age more than 18 years old with hematologic malignancy 2. Admit at medicine and hemato-oncological ward 3. Develop febrile neutropenia as definition of IDSA 2010
Exclusion criteria
Exclusion criteria: 1. Previously documented multi-drug resistance organisms within 1 month 2. Previous history of adverse reaction or allergy to piperacillin/tazobactam or meropenem 3. Septic shock or sepsis related hypotension required vasopressor 4. Pregnancy and lactation 5. Expose to antibiotic treatment more than 24 hours prior to enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response 14 days after treatment All of the followings must be achieved: 1. Afebrile (T<38 c) at least 3 consecutive days, 2. Improve | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality 28 day after treatment Mortality rate,Duration of fever Until fever defervescence Days,Adverse drug reaction Until end of treatment Clinical and laboratory assessment | — |
Contacts
Public ContactMethee Chayakulkeeree
Faculty of Medicine Siriraj Hospital
Outcome results
None listed